ZURICH, Oct 25 (Reuters) - Novartis AG said on Thursday it was confident of the safety of two flu vaccines produced at its Italian site and had witnessed no safety concerns to date.
On Wednesday, Italy banned the sales and use of four anti-influenza vaccines produced by Novartis pending tests for possible side effects.
The Swiss health watchdog later followed suit, issuing a precautionary halt to deliveries of the vaccines Agrippal and Fluad, which are manufactured in Italy.
Novartis said the move by the Italian health ministry followed a report by the drugmaker of small particles in the vaccines. It said it had already provided the ministry with an assessment confirming the safety of the vaccines.
"Novartis confirms that these particles can occur in the vaccine manufacturing process and is confident that there is no impact on the safety or efficacy of the vaccine," it said in a statement.
The company said it would continue to cooperate with Italian health authorities to understand the reasons for their decision, and remained committed to patient safety. (Reporting by Caroline Copley; Editing by Daniel Magnowski)
.inode/image/byInode/1/filter/Resize,Jpeg/jpeg_q/90/resize_w/187)
.inode/image/byInode/1/filter/Resize,Jpeg/jpeg_q/90/resize_w/187)
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.
comments powered by Disqus